Bg pattern

Colobreathe 1,662,500 IU powder for inhalation, hard capsules

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use Colobreathe 1,662,500 IU powder for inhalation, hard capsules

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Package Leaflet: Information for the User

Colobreathe 1.662.500 UI powder for inhalation, hard capsules

colistimethate sodium

Read all of this leaflet carefully before you start using this medicine, because it contains important information for you.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor or pharmacist.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the pack

  1. What is Colobreathe and what is it used for
  2. What you need to know before you use Colobreathe
  3. How to use Colobreathe
  4. Possible side effects
  5. Storing Colobreathe
  6. Contents of the pack and other information

1. What is Colobreathe and what is it used for

Colobreathe contains colistimethate sodium, a type of antibiotic called polymyxin.

Colobreathe is used to control persistent lung infections caused by the bacterium Pseudomonas aeruginosain adult and child patients 6 years of age and older with cystic fibrosis. Pseudomonas aeruginosais a very common bacterium that infects almost all patients with cystic fibrosis at some point in their lives. Some people get this infection while they are very young, but for others it happens much later. If this infection is not properly controlled, it will cause lung damage.

How it works

Colobreathe works by destroying the bacterial cell membrane, with a lethal effect on these bacteria.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before you use Colobreathe

Do not use Colobreathe:

  • if you/your child is allergic to colistimethate sodium, colistin sulfate or polymyxins.

Warnings and precautions

Talk to your doctor or pharmacist before you start using Colobreathe.

Tell your doctor if you/your child has ever suffered from any of the following conditions:

  • has previously reacted badly to the inhalation of dry powder medicines, unless this has already been discussed with your doctor.
  • already has a known muscle disease called myasthenia gravis or the hereditary disease porphyria
  • blood in the sputum (the matter you cough up)

After each inhalation of Colobreathe, you should rinse your mouth with water. The rinse should not be swallowed. The rinse can reduce the risk of developing oral fungal infections during treatment and can also reduce the unpleasant taste associated with colistimethate sodium.

When you/your child starts using Colobreathe, you/your child may find that you have a cough, difficulty breathing, chest tightness or wheezing (a whistling sound that occurs when breathing). The number of these side effects can be reduced as you continue to use the inhaler or your doctor may prescribe a bronchodilator for you to use before or after taking Colobreathe. If any of these effects become a problem, please contact your doctor who may change your treatment.

If you/your child has any kidney or nerve problems, you should be extremely careful when taking Colobreathe, although your doctor will already be aware of this.

If you/your child needs to take other forms of colistimethate, either by injection or by nebulisation, you should be extremely careful, although your doctor will already be aware of this.

Children

Do not give Colobreathe to children under 6 years of age, as it is not suitable for them.

Other medicines and Colobreathe

Tell your doctor if you/your child is taking, has recently taken or might take any other medicines, and in particular:

  • if you/your child is taking aminoglycoside antibiotics used to treat infections, you should be extremely careful;
  • if you/your child has myasthenia gravis and is taking macrolide antibiotics such as azithromycin and clarithromycin, or fluoroquinolones such as norfloxacin and ciprofloxacin. Taking these at the same time as Colobreathe may cause muscle weakness problems;
  • if you/your child is taking colistimethate by injection or nebulisation, you should be extremely careful;
  • if you/your child needs a general anaesthetic, you should be extremely careful.

Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

There is no information on the safety of Colobreathe in pregnant women. Your doctor will advise you on whether the benefits of the medicine outweigh the risks.

Colistimethate sodium may pass into breast milk. Discuss the use of Colobreathe with your doctor.

Driving and using machines

You may experience dizziness, confusion or have problems with your vision while using Colobreathe. Do not drive or operate machinery until the symptoms have disappeared.

Colobreathe contains sodium

This medicine contains less than 1 mmol of sodium (23 mg) per capsule; this is essentially “sodium-free”.

3. How to use Colobreathe

Follow the instructions for administration of the medicine contained in this leaflet or as directed by your doctor. If you are in doubt, ask your doctor if you/your child has doubts.

The first dose should be given under medical supervision.

The recommended dose is

Adults and children 6 years of age and older

  • The contents of one Colobreathe capsule should be inhaled twice a day using the Turbospin inhaler.
  • There should be a 12-hour gap between doses.

The order in which you should take or perform other treatments

If you/your child is taking other treatments for cystic fibrosis, you/your child should take them in the following order:

  • Inhaled bronchodilators
  • Respiratory physiotherapy
  • Other inhaled medicines
  • Then Colobreathe

You/your child should confirm the order of your treatments with your doctor.

Turbospin inhaler with diagram of its parts: clip, hood, mouthpiece, air inlet, spray chamber, handle and piston

Method of administration

Colobreathe is inhaled into the lungs as a powder from the capsule using the manual inhaler called Turbospin. Colobreathe can only be administered using this device.

Do not swallow Colobreathe capsules.

To inhale Colobreathe from the capsule using the Turbospin inhaler, follow the procedure described below. Your doctor, pharmacist or nurse should show you/your child how to inhale the medicine when you/your child start treatment:

Using Colobreathe with the Turbospin inhaler

Preparing the Turbospin

Hand holding a white auto-injector with a red arrow indicating the direction of injection on the thumb

  1. Remove the hood by gently pulling it off.

Hands holding a white device with two cylindrical parts and red arrows indicating rotation for connection

  1. Unscrew the mouthpiece, exposing the Turbospin inhaler chamber.

Hand holding a white medicinal patch with a transparent protective strip and red arrow indicating its removal

  1. Remove one capsule from the blister pack. Once you have removed the capsule, you must use it immediately.

White capsule being connected to a white applicator with a red arrow indicating the direction

  1. Gently insert the capsule into the chamber with the wider end first. Do not force it.

Hands holding a white auto-injector with pink arrows indicating the direction of rotation of the device

  1. Now replace the mouthpiece by screwing it back into place.

Piercing the capsule and inhaling the medicine

Hand holding a white medicine applicator with a transparent cylinder and red arrow indicating direction

  1. To pierce the capsule:
  • Hold the inhaler with the mouthpiece upwards, gently push the piston upwards until you reach the visible line; you will feel resistance at this point and this will fix the capsule in place, ready to be pierced. Hold this position before proceeding to pierce.
  • Now, with the capsule in place, continue to push the piston until you reach the stop and then release it.
  • The capsule is now pierced and the contents can be inhaled.
  • Do notpierce the capsule more than once. You may see a little powder coming out of the capsule chamber after piercing, which is normal.

Patient holding a white oral inhaler near their lips to administer the medication

  1. Exhale slowly. Place the mouthpiece between your lips and teeth. Make sure you create a seal between your lips and the mouthpiece. Be careful not to block the air inlets with your fingers or mouth during inhalation.
  2. Then, inhale slowly and deeply through your mouth at a rate that allows you to hear or feel the capsule spinning.
  3. Remove the Turbospin inhaler from your mouth and hold your breath for about 10 seconds, or for as long as you feel comfortable, then exhale slowly.
  4. If you do not hear the capsule spinning, it may be stuck in the compartment. If this happens, you can release it by gently tapping the inhaler chamber. Do not try to release the capsule by repeatedly pressing the piston. If the capsule cannot be released and the powder cannot be inhaled, discard the broken capsule and any remaining powder in it and use another one.
  5. Inhale the medicine again by repeating steps 7 and 8 to make sure you have emptied the capsule.
  6. You can check if the capsule is empty by unscrewing the mouthpiece and checking the capsule. If it is not empty, repeat steps 7, 8 and 9 until you have inhaled all the contents.
  7. When you have inhaled all the contents, rinse your mouth well with water and then spit it out.

Removing the empty capsule from the Turbospin

  1. When the capsule is empty, unscrew the mouthpiece, then remove and discard the empty capsule.

Additional information

When you breathe in slowly, you draw air through the body of the Turbospin inhaler into the capsule chamber. The tiny particles of medicine from the capsule are picked up by the airflow and carried through your airways to your lungs.

Occasionally, very small pieces of the capsule casing may enter your mouth or airways.

  • If this happens, you may notice these pieces on your tongue or in your airways.
  • The capsule casing is made of gelatine, which is harmless to humans if swallowed or inhaled.
  • The chances of the capsule breaking into pieces increase if the capsule is pierced more than once during step 6.

Cleaning the Turbospin device

Clean the Turbospin inhaler after each dose using the following procedure:

  1. Press the piston all the way down a couple of times while keeping the chamber mouth downwards.
  2. Wipe the chamber with a cloth or cotton swab. Do not use water.
  3. Screw the mouthpiece firmly back into place, put the cap on and the inhaler will be ready to use for the next dose.

If you/your child uses more Colobreathe than you should, or if you have accidentally swallowed a capsule,contact your doctor immediately for help.

If you/your child misses a dose of Colobreathe

If you/your child forgets to take a dose of Colobreathe, then you/your child should take the missed dose as soon as you/your child remembers. You/your child should not take 2 doses in less than 12 hours. Continue from there as directed.

If you/your child stops treatment with Colobreathe

Do not stop your treatment prematurely unless your doctor tells you to. Your doctor will decide how long your treatment/your child’s treatment should last.

If you/your child has any other questions about the use of this medicine, ask your doctor.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Allergic reactions

An allergic reaction with Colobreathe is possible (usually serious allergic reactions can cause skin rash, swelling of the face, tongue and throat, difficulty breathing due to narrowing of the airways and loss of consciousness). If you/your child experiences signs of an allergic reaction, you must seek urgent medical attention.

Other possible side effects

You/your child may have an unpleasant taste in your mouth after inhaling Colobreathe.

Very common (may affect more than 1 in 10 people):

  • Difficulty breathing
  • Cough, sore throat
  • Hoarse or weak voice, or even loss of voice
  • Unpleasant taste

Common (may affect up to 1 in 10 people):

  • Headache
  • Ringing or buzzing in the ears, balance problems.
  • Coughing up blood, wheezing (a whistling sound that occurs when breathing), chest discomfort, asthma, productive cough (cough that produces mucus), lung infection, crackling in the lungs (your doctor hears this when listening to your lungs with a stethoscope)
  • Vomiting, nausea
  • Changes in your lung function (found in tests)
  • Joint pain
  • Lack of energy, tiredness
  • Increased temperature

Uncommon (may affect up to 1 in 100 people):

  • Allergic reactions (hypersensitivity); the signs may include rash and itching
  • Weight fluctuations, decreased appetite
  • Anxiety
  • Seizures
  • Drowsiness
  • Ear blockage
  • Chest pain
  • Difficulty breathing
  • Nosebleeds, runny nose (mucus in the nose, which can make you feel blocked), cough with thick green mucus, sore throat and sinuses
  • Abnormal sounds in the chest (your doctor would hear this when listening to your lungs with a stethoscope)
  • Diarrhoea, gas
  • Excessive saliva production
  • Toothache
  • Protein in the urine (found in tests)
  • Thirst

The side effects described above have been seen in people of all ages with a similar frequency.

Reporting of side effects

If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly through the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storing Colobreathe

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the outer packaging and on the blister pack after EXP. The expiry date is the last day of the month shown.

Do not store Colobreathe above 25°C.

Store in the original package to protect from moisture.

If you/your child accidentally peels off the foil and a capsule is exposed, please discard that capsule.

Discard the Turbospin inhaler after completion of a treatment pack.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.

6. Container contents and additional information

Composition of Colobreathe

The active ingredient is sodium colistimethate. Each capsule contains 1,662,500 IU (approximately equivalent to 125 mg) of sodium colistimethate.

The other components are:

Capsule shell

Gelatin

Polyethylene glycol

Sodium lauryl sulfate

Purified water

Appearance of the product and container contents

Colobreathe powder for inhalation, hard capsule (powder for inhalation) is supplied in small, hard, transparent gelatin capsules containing a fine white powder.

The Turbospin is a dry powder inhaler driven by the inspiratory flow, manufactured from polypropylene and stainless steel.

The capsules are packaged in blisters, which are supplied in boxes containing:

  • 56 hard capsules and a Turbospin dry powder inhaler device, sufficient for 4 weeks of use.
  • 8 hard capsules and a Turbospin dry powder inhaler device, sufficient for 4 days of use.

Only some pack sizes may be marketed.

Marketing authorization holder

Essential Pharma Limited,

Vision Exchange Building,

Territorials Street, Zone 1,

Central Business District,

Birkirkara, CBD 1070,

Malta

Manufacturer

Teva Pharmaceuticals Europe BV

Swensweg 5

2031 GA Haarlem

Netherlands.

Millmount Healthcare Limited

Block 7, City North Business Campus

Stamullen

Co Meath

K32 YD60

Ireland

Merckle GmbH

Ludwig-Merckle-Str-3

89143 Blaubeuren

Germany

Laboratorios Liconsa, S.A.

Miralcampo Avenue, 7, Industrial Estate

Miralcampo

19200 Azuqueca de Henares (Guadalajara)

Spain

Date of last revision of this leaflet: February 2024.

Detailed information on this medicinal product is available on the European Medicines Agency website: http://www.ema.europa.eu. There are also links to other websites on rare diseases and orphan medicines.

Online doctors for Colobreathe 1,662,500 IU powder for inhalation, hard capsules

Discuss questions about Colobreathe 1,662,500 IU powder for inhalation, hard capsules, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

5.0 (69)
Doctor

Tarek Agami

General medicine 11 years exp.

Dr. Tarek Agami is a general practitioner registered in both Portugal and Israel, with broad experience in family and preventive medicine. He offers online consultations for adults and children, providing personalised support for primary care needs, chronic disease management, and everyday health concerns.

Dr. Agami received clinical training and worked in leading medical institutions in Israel (Kaplan Medical Center, Barzilai Medical Center, Wolfson Medical Center) and Portugal (European Healthcare City, Viscura Internacional, Hospital Dr. José Maria Grande, Hospital Vila Franca de Xira). His approach combines international medical standards with individualised attention to each patient.

Main areas of consultation:

  • Diagnosis and treatment of acute and chronic conditions (high blood pressure, diabetes, respiratory infections, cardiovascular symptoms)
  • Evaluation of symptoms and guidance on further diagnostic testing
  • Preventive check-ups and regular health monitoring
  • Medical support during travel or after relocation
  • Treatment adjustments and lifestyle recommendations based on your personal history
Dr. Agami provides medical support for patients using GLP-1 medications (such as Ozempic or Mounjaro) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Portugal and Israel.

Dr. Agami is committed to evidence-based, patient-centred care, ensuring that each person receives trusted medical support tailored to their health goals.

Camera Book a video appointment
€69
5.0 (63)
Doctor

Nuno Tavares Lopes

Family medicine 18 years exp.

Dr. Nuno Tavares Lopes is a licensed physician in Portugal with 17 years of experience in emergency medicine, family and general practice, and public health. He is the Director of Medical and Public Health Services at an international healthcare network and serves as an external consultant for the WHO and ECDC.

  • Emergency care: infections, fever, chest/abdominal pain, minor injuries, paediatric emergencies
  • Family medicine: hypertension, diabetes, cholesterol, chronic disease management
  • Travel medicine: pre-travel advice, vaccinations, fit-to-fly certificates, travel-related illnesses
  • Sexual and reproductive health: PrEP, STD prevention, counselling, treatment
  • Weight management and wellness: personalised weight loss programmes, lifestyle guidance
  • Skin and ENT issues: acne, eczema, allergies, rashes, sore throat, sinusitis
  • Pain management: acute and chronic pain, post-surgical care
  • Public health: prevention, health screenings, long-term monitoring
  • Sick leave (Baixa médica) connected to Segurança Social in Portugal
  • IMT medical certificates for driving licence exchange
Dr. Nuno Tavares Lopes provides medical support for patients using GLP-1 medications (Mounjaro, Wegovy, Ozempic, Rybelsus) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Europe.

Dr. Lopes also provides interpretation of medical tests, follow-up care for complex patients, and multilingual support. Whether for urgent concerns or long-term care, he helps patients act with clarity and confidence.

Camera Book a video appointment
€59
5.0 (17)
Doctor

Anastasiia Shalko

Family medicine 13 years exp.

Dr. Anastasiia Shalko is a general practitioner with a background in both paediatrics and general medicine. She graduated from Bogomolets National Medical University in Kyiv and completed her paediatric internship at the P.L. Shupyk National Medical Academy of Postgraduate Education. After working as a paediatrician in Kyiv, she relocated to Spain, where she has been practising general medicine since 2015, providing care for both adults and children.

Her work focuses on urgent, short-term medical concerns – situations where patients need quick guidance, symptom assessment and clear next steps. She helps people understand whether their symptoms require in-person evaluation, home management or a change in treatment. Common reasons for booking an online consultation include:

  • acute respiratory symptoms (cough, sore throat, runny nose, fever)
  • viral illnesses such as colds and seasonal infections
  • gastrointestinal complaints (nausea, diarrhoea, abdominal pain, gastroenteritis)
  • sudden changes in how a child or adult feels
  • questions about existing treatment and whether adjustments are needed
  • renewal of prescriptions when clinically appropriate
Dr. Shalko works specifically with urgent and short-term problems, providing practical recommendations and helping patients determine the safest next step. She explains symptoms clearly, guides patients through decision-making and offers straightforward medical advice for everyday acute issues.

She does not provide long-term management of chronic conditions, ongoing follow-up or comprehensive care plans for complex long-term illnesses. Her consultations are designed for acute symptoms, sudden concerns and situations where timely medical input is important.

With clinical experience in both paediatrics and general medicine, Dr. Shalko confidently supports adults and children. Her communication style is clear, simple and reassuring, helping patients feel informed and supported throughout the consultation.

Camera Book a video appointment
€50
5.0 (3)
Doctor

Tomasz Grzelewski

Dermatology 21 years exp.

Dr Tomasz Grzelewski is an MD, PhD specialist in allergy, paediatrics, general practice and sports medicine, with a clinical focus on dermatology, endocrinology, allergology and sports-related health. He has more than 20 years of clinical experience and completed his medical training at the Medical University of Łódź, where he defended his PhD thesis with distinction. His doctoral research was recognised by the Polish Society of Allergology for its innovative contribution to the field. Throughout his career, he has gained extensive expertise in diagnosing and managing a wide range of allergic and paediatric conditions, including modern allergen desensitisation techniques.

For five years, Dr Grzelewski served as the Head of two paediatric departments in Poland, managing complex clinical cases and leading multidisciplinary teams. He also worked in medical centres in the United Kingdom, gaining experience across both primary care and specialist environments. With over a decade of telemedicine experience, he has provided online consultations across Europe and is valued for his clear, structured and evidence-based medical guidance.

Dr Grzelewski is actively involved in clinical programmes focused on modern anti-allergic therapies. As a Principal Investigator, he leads research projects on sublingual and oral allergen desensitisation, supporting evidence-based progress in allergy treatment for both children and adults.

In addition to his background in allergology and paediatrics, he completed dermatology studies through the Cambridge Education Group (Royal College of Physicians of Ireland) and a Clinical Endocrinology course at Harvard Medical School. This advanced training enhances his ability to manage skin manifestations of allergies, atopic conditions, urticaria, endocrine-related symptoms and complex immunological reactions.

Patients commonly seek his care for:

  • seasonal and perennial allergies
  • allergic rhinitis and chronic nasal symptoms
  • asthma and breathing difficulties
  • food and medication allergies
  • urticaria, atopic dermatitis and skin reactions
  • recurrent infections in children
  • sports-related health questions
  • general family medicine concerns
Dr Tomasz Grzelewski is known for his clear communication style, structured medical approach and ability to explain treatment options in a concise and accessible way. His multidisciplinary background across allergy, paediatrics, dermatology and endocrinology allows him to provide safe, up-to-date and comprehensive care for patients of all ages.
Camera Book a video appointment
€80

Frequently Asked Questions

Is a prescription required for Colobreathe 1,662,500 IU powder for inhalation, hard capsules?
Colobreathe 1,662,500 IU powder for inhalation, hard capsules requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in Colobreathe 1,662,500 IU powder for inhalation, hard capsules?
The active ingredient in Colobreathe 1,662,500 IU powder for inhalation, hard capsules is colistin. This information helps identify medicines with the same composition but different brand names.
Who manufactures Colobreathe 1,662,500 IU powder for inhalation, hard capsules?
Colobreathe 1,662,500 IU powder for inhalation, hard capsules is manufactured by Essential Pharma Limited. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of Colobreathe 1,662,500 IU powder for inhalation, hard capsules online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether Colobreathe 1,662,500 IU powder for inhalation, hard capsules is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to Colobreathe 1,662,500 IU powder for inhalation, hard capsules?
Other medicines with the same active substance (colistin) include COLFINAIR 1 Million IU Powder for Solution for Nebulizer Inhalation, COLFINAIR 2 MILLION IU POWDER FOR SOLUTION FOR NEBULIZER INHALATION, SODIUM COLISTIMETHATE ACCORD 1 Million IU POWDER FOR INJECTABLE SOLUTION AND FOR INFUSION. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media